Page 2537 - Hematology_ Basic Principles and Practice ( PDFDrive )

2260 Part XIII Consultative Hematology

taxanes, and corticosteroids) is less likely to be associated with
BOX 156.1 Recommendations for Patients
interactions. Caution should be taken with other agents (e.g.,
“All patients with hematologic problems should be asked specifically antiangiogenic agents, tyrosine kinase inhibitors) for which there
about their use of complementary and alternative therapies.” is insufficient information.
“All patients with hematologic problems should receive guidance
about the advantages and limitations of complementary therapies in
an open, evidence-based, and patient-centered manner by a qualified
professional.” REFERENCES
Adapted from Deng GE, Cassileth BR, Cohen L, et al: Integrative oncology
practice guidelines. J Soc Integr Oncol 5:65, 2007. 1. Schultz AM, Chao SM, McGinnis JM: Integrative medicine and the health
of the public: a summary of the February 2009 summit, Washington, DC,
Institute of Medicine, 2009, National Academies Press.
2. McGuire S: Complementary and alternative medicine in the United
concern is that antioxidants might somehow interfere with or coun- States, Washington, DC, 2005, National Academies Press. Institute of
teract the activities of these anticancer agents. However, to date, Medicine.
preclinical experiments and clinical studies have not definitively 3. Clarke TC, Black LI, Stussman BJ, et al: Trends in the use of complemen-
48
shown impact on treatment outcome. Of particular note, an obser- tary health approaches among adults: United States 2002-2012, National
vational cohort study from the Fred Hutchinson Cancer Research Health Statistics Report; no 79, Hyattsville, MD, National Center for
Center in Seattle evaluating the prevalence of supplement use in Health Statistics, 2015.
persons before receiving hematopoietic stem cell transplant (HSCT) 4. Gansler T, Kaw C, Crammer C, et al: A population-based study of
and the association of select supplements with outcomes found that prevalence of complementary methods use by cancer survivors: a report
pretransplant intake of vitamin C (≥500 mg/day) or vitamin E from the American Cancer Society’s studies of cancer survivors. Cancer
(≥400 IU/day) was associated with increased risk of relapse or mortal- 113:1048, 2008.
49
ity. Others have reported deficiencies before and immediately after 5. Snyderman R, Weil AT: Integrative medicine: bringing medicine back to
50
HSCT. However, few clinical studies have built upon observational its roots. Arch Intern Med 162:395, 2002.
studies. One small study performed among patients with AML and 6. Eisenberg DM, Kessler RC, Van Rompay M, et al: Perceptions about
ALL undergoing HSCT (NCT01432873) randomized adults (n = complementary therapies relative to conventional therapies among adults
77) to selenium (200 µg, twice daily) or placebo beginning on the who use both; results from a national survey. Ann Intern Med 135:344,
day of conditioning therapy and continuing to day 14 post-HSCT. 2001.
51
No effect on proinflammatory cytokines were observed. Another 7. Sparreboom A: Herbal remedies in the United States: potential interac-
small study investigated the addition of vitamin C to conventional tions with anticancer agents. J Clin Oncol 22:2489, 2004.
treatment for acute promyelocytic leukemia; no beneficial effects on 8. Kelly KM: Bringing evidence to complementary and alternative medi-
outcome were observed. 52 cine in children with cancer: Focus on nutrition-related therapies. Pediatr
Recent studies have shown interactions of antioxidant supple- Blood Cancer 50:490, 2008. discussion 8.
ments with the proteasome inhibitor bortezomib. Vitamin C, at 9. Sencer SF, Kelly KM: Bringing evidence to complementary and alterna-
orally achievable concentrations (equivalent to 1 g/day, a dose fre- tive medicine for children with cancer. J Pediatr Hematol Oncol 28:186,
quently used by patients), inhibited the in vitro multiple myeloma 2006.
cell cytotoxicity of bortezomib and blocked its inhibitory effect on 10. Valji R, Adams D, Daganis S, et al: Complementary and alternative
20S proteasome activity. In addition, green tea polyphenols and medicine: a survey of its use in pediatric oncology. Evid Based Comple-
dietary supplements carrying hydroxyl groups, including flavonoid ment Alternat Med 2013:527163, 2013.
compounds such as quercetin, bind and inhibit the activity of bort- 11. O.Connor N, Graham D, O’Meara A, et al: The use of complementary
ezomib on malignant B cells and multiple myeloma cells in vitro, and alternative medicine by Irish pediatric patients. J Pediatr Hematol
although by mechanisms independent of their antioxidant activity. Oncol 35:537–542, 2013.
Taken together, these studies suggest that antioxidant supplements 12. Wesa KM, Cassileth BR: Is there a role for complementary therapy in
should be avoided in patients taking bortezomib and other boronic the management of leukemia? Expert Rev Anticancer Ther 9:1241, 2009.
acid proteasome inhibitor therapy. 13. Barton DL, Loprinzi C, Jatoi A, et al: Can complementary and alterna-
The precise role of antioxidant supplementation in the patients tive medicine clinical cancer research be successfully accomplished? The
with hematologic malignancies remains to be determined. Studies Mayo Clinic-North Central Cancer Treatment Group experience. J Soc
adequately evaluating the impact of supplementation on toxicity and Integr Oncol 4:143, 2006.
disease-free survival have not yet adequately demonstrated that the 14. Verhoef MJ, Leis A: From studying patient treatment to studying patient
benefits of supplementation clearly outweigh the risks; therefore the care: arriving at methodologic crossroads. Hematol Oncol Clin North Am
possibility of harm must be strongly considered (Box 156.1). Recom- 22:671, viii–ix, 2008.
mendations for clinical practice at the present time include the 15. Yeung KS, Gubili J, Cassileth B: Evidence-based botanical research:
following: applications and challenges. Hematol Oncol Clin North Am 22:661. viii,
2008.
• Patients should be advised to avoid dietary antioxidant supple- 16. Weiger W, Smith M, Boon H, et al: Advising patients who seek comple-
ments above the basic nutritional requirements as defined by the mentary and alternative medical therapies for cancer. Ann Intern Med
National Academy of Science, Dietary Reference Intakes during 137:889, 2002.
radiation therapy and stem cell transplantation. Until safety data 17. Gordon JS: Mind-body medicine and cancer. Hematol Oncol Clin North
is available, doses should not exceed the upper tolerable limit Am 22:683. ix, 2008.
during treatment. 18. Dusek J, et al: Stress management versus life-style modification on
• Patients should avoid dietary antioxidant supplements while systolic hypertension and medication elimination, a randomized trial.
receiving bortezomib and other boronic acid proteasome inhibitor J Altern Complement Med 2:129–138, 2008.
therapy. Counseling patients to avoid supplementation while 19. Niles H, Mehta DH, Corrigan AA, et al: Functional genomics in the
receiving chemotherapy associated with high oxidative stress study of mind-body therapies. Ochsner J 14:681–695, 2014.
(anthracyclines, alkylating agents, platinum-containing agents, 20. Rossman M, Shrock D: Mind-body medicine in integrative cancer care.
topoisomerase I and II inhibitors) is encouraged. In Abrams D, Weil A, editors: Integrative oncology, New York, 2009,
• Use of antioxidant supplements while receiving chemotherapy Oxford University Press, p 244.
associated with low oxidative stress (purine or pyrimidine ana- 20a. Park ER, et al: A relaxation response training for women undergoing
logues, antimetabolites, monoclonal antibodies, vinca alkaloids, breast biopsy: exploring integrated care. Breast 22(5):799–805, 2013.